Search Results 821-830 of 23847 for autoimmune hepatitis
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
A Study of the Effectiveness and Safety of Subcutaneous Semaglutide for Patients with Fatty-Liver Disease, not Caused by Alcoholism · More about research at Mayo ...
'Zombie' cells spark inflammation in severe fatty liver disease, Mayo Clinic researchers find. ROCHESTER, Minn. — Mayo Clinic researchers have uncovered how ...
Hepatitis C, Hepatitis B, Nonalcoholic fatty liver disease, Cirrhosis, Alcoholic hepatitis, Hepatic encephalopathy, Vir...al hepatitis. Show more areas of ...
Kidney failure, acute or; Liver disease (including hepatitis) or; Osteomalacia (soft bones) or; Osteoporosis (weak or brittle bones)—Use with caution. May make ...
Hepatitis B virus (HBV) infection is a global health problem because individuals infected with the virus are at risk of chronic hepatitis, liver cirrhosis and ...
Learn how the immune system mistakenly attacks brain cells to cause swelling in the brain related to this group of conditions.
Participation eligibility · Existing chronic liver disease (liver cirrhosis). · Concomitant infection with HIV or Chronic hepatitis B. · Patient or any member of ...
Viral hepatitis. Here's a closer look at the ... liver disease. Development of a bioartificial ... Evaluating the safety and effectiveness of bariatric procedures ...
A Study to Evaluate the Effectiveness and Safety of Elafibranor for Patients with Nonalcoholic Fatty Liver Disease · Overview · Participation eligibility.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!